SEATTLE, Dec. 8, 2020 /PRNewswire/ -- CTI BioPharma
Corp. (NASDAQ: CTIC) today announced that management will provide a
corporate overview at The JMP Securities Hematology Summit at
3:00 p.m. EST. The conference will be
held in a virtual meeting format.
Presentation details:
Event: The JMP Securities Hematology Summit
Date: Tuesday, Dec. 15
Time: 3:00 p.m. EST
The presentation will be webcast live and available for replay
from the Investors section of CTI BioPharma's website at
www.ctibiopharma.com.
About CTI BioPharma Corp.
We are a
biopharmaceutical company focused on the acquisition, development
and commercialization of novel targeted therapies for blood-related
cancers that offer a unique benefit to patients and their
healthcare providers. We concentrate our efforts on treatments that
target blood-related cancers where there is an unmet medical need.
In particular, we are focused on evaluating pacritinib, our sole
product candidate currently in active late-stage development, for
the treatment of adult patients with myelofibrosis. In addition, we
have recently started developing pacritinib for use in hospitalized
patients with severe COVID-19, in response to the COVID-19
pandemic. We are headquartered in Seattle, Washington.
CTI BioPharma Investor Contacts:
Maeve Conneighton/Maghan
Meyers
+212-600-1902
cti@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-jmp-securities-hematology-summit-on-tuesday-dec-15-301187816.html
SOURCE CTI BioPharma Corp.